Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs.
BACKGROUND
Radioiodine therapy (131I) for the treatment of hyperthyroidism has been shown to be effective and safe. Despite the extensive experience with radioiodine therapy, the necessity for pretreatment with antithyroid drugs is controversial. Pretreatment is partly based on the concept that antithyroid drugs deplete the thyroidal hormonal stores, thereby reducing the risk of a radioiodine-induced aggravation of hyperthyroidism or thyroid storm. Few data are available on the frequency of clinically significant exacerbations of hyperthyroidism following 131I therapy without prior treatment with antithyroid drugs. The aim of the present study was to determine prospectively the early clinical and biochemical changes after 131I therapy in patients who were not pretreated with antithyroid drugs.


METHODS
Patients with Graves' disease (n = 21), toxic multinodular goiter (n = 11) or toxic adenoma (n = 2) were studied before and after 131I therapy. Clinical and biochemical parameters of thyroid function were investigated before and 1, 2, 8, 11, 18 and 25 days after 131I treatment. Patients were given no antithyroid drugs prior to 131I therapy, all patients received beta-blocking agents for symptomatic relief.


RESULTS
In 19 of 34 patients, a transient increase in thyroid hormone levels was observed, predominantly in the first week following 131I therapy. None of these patients experienced worsening of thyrotoxic symptoms. This transient increase in thyroid hormone levels was demonstrated in all patients with toxic multinodular goiter, whereas it was found in only six of 21 patients with Graves' disease. This difference could not readily be explained by differences in pretreatment thyroid hormone levels, administered dose or effectively absorbed dose of 131I.


CONCLUSIONS
131I treatment of hyperthyroidism without pretreatment with antithyroid drugs may cause a transient increase in thyroid hormone levels. Clinically significant exacerbations of hyperthyroidism were, however, not observed in our study population. Increased hormone levels following 131I therapy were more often seen in patients with toxic multinodular goiter than in patients with Graves' disease.
Koornstra
J J
JJ
Department of Internal Medicine, MCL-Zuid, Leeuwarden, The Netherlands.
Kerstens
M N
MN
Hoving
J
J
Visscher
K J
KJ
Schade
J H
JH
Gort
H B
HB
Leemhuis
M P
MP
D000236:Adenoma / Q000150:complications; D000328:Adult; D000368:Aged; D013956:Antithyroid Agents / Q000627:therapeutic use; D016903:Drug Monitoring; D005260:Female; D006044:Goiter, Nodular / Q000150:complications; D006111:Graves Disease / Q000150:complications; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D007457:Iodine Radioisotopes / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011292:Premedication / Q000379:methods; D011446:Prospective Studies; D013960:Thyroid Function Tests; D013963:Thyroid Hormones / Q000097:blood; D013964:Thyroid Neoplasms / Q000150:complications; D016896:Treatment Outcome
D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D013963:Thyroid Hormones